Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial.

Dal Pra, A; Ghadjar, P; Hayoz, S; Liu, V Y T; Spratt, D E; Thompson, D J S; Davicioni, E; Huang, H-C; Zhao, X; Liu, Y; Schär, C; Gut, P; Plasswilm, L; Hölscher, T; Polat, B; Hildebrandt, G; Müller, A-C; Pollack, A; Thalmann, G N; Zwahlen, D; ... (2022). Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial. Annals of oncology, 33(9), pp. 950-958. Elsevier 10.1016/j.annonc.2022.05.007

[img]
Preview
Text
1-s2.0-S0923753422012054-main.pdf - Accepted Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase 3 trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy.

PATIENTS AND METHODS

A clinical grade whole-transcriptome assay was performed on RP samples obtained from patients enrolled in SAKK 09/10, a phase 3 trial of 350 men with biochemical recurrence post-radical prostatectomy randomized to 64Gy vs. 70Gy without concurrent hormonal therapy or pelvic nodal radiotherapy (RT). A pre-specified statistical plan was developed to assess the impact of the GC on clinical outcomes. The primary endpoint was biochemical progression; secondary endpoints were clinical progression and time to hormone therapy. Multivariable analyses adjusted for age, T-category, Gleason score, post-radical prostatectomy persistent prostate-specific antigen (PSA), PSA at randomization, and randomization arm were conducted, accounting for competing risks.

RESULTS

The analytic cohort of 226 patients was representative of the overall trial, with median follow-up of 6.3 years (IQR 6.1-7.2). GC (high vs. low-intermediate) was independently associated with biochemical progression (subdistribution hazard ratio [sHR] 2.26 [95% CI 1.42-3.60], p<0.001), clinical progression (HR 2.29 [95% CI 1.32-3.98], p=0.003), and use of hormone therapy (sHR 2.99 [95% CI 1.55-5.76], p=0.001). GC high patients had 5-year freedom from biochemical progression of 45% vs. 71% for GC low-intermediate. Dose escalation did not benefit the overall cohort, nor patients with lower vs. higher GC scores.

CONCLUSIONS

This study represents the first contemporary randomized controlled trial in patients treated with early SRT without concurrent hormone therapy or pelvic nodal RT that has validated the prognostic utility of the GC. Independent of standard clinicopathologic variables and RT dose, high-GC patients were more than twice as likely than lower-GC patients to experience biochemical and clinical progression and receive of salvage hormone therapy. This data confirms the clinical value of Decipher GC to personalize the use of concurrent systemic therapy in the postoperative salvage setting.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Dal Pra, Alan, Plasswilm, Ludwig, Thalmann, George, Aebersold, Daniel Matthias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1569-8041

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

01 Jun 2022 11:26

Last Modified:

05 Dec 2022 16:20

Publisher DOI:

10.1016/j.annonc.2022.05.007

PubMed ID:

35636621

Uncontrolled Keywords:

Biomarkers Decipher postoperative radiotherapy prognosis prostate cancer salvage radiotherapy

BORIS DOI:

10.48350/170376

URI:

https://boris.unibe.ch/id/eprint/170376

Actions (login required)

Edit item Edit item
Provide Feedback